GENinCode collaborates with Sohin Genetics for heart disease test

(Alliance News) - GENinCode PLC on Wednesday said it has entered a commercial agreement with a Mexican healthcare provider for the distribution of its polygenic risk score test for heart health.

The Oxford-based genetic testing company, focused on cardiovascular disease and ovarian cancer prevention, said Sohin Genetics will commercially promote and market Cardio inCode-Score in the Mexican market.

This will include training, sample handling and ordering via the GENinCode 'SITAB' international reporting system, GENinCode said.

Cardio inCode-Score is a polygenic risk score based on DNA extracted from a saliva or blood sample which identifies an individual's inherited genetic risk of heart disease.

Wednesday's announcement follows a recent collaboration between GENinCode and the Mexican Association for the Prevention of Atherosclerosis, the company said.

"We are delighted to announce this latest distribution agreement with Sohin Genetics to sell Cardio inCode-Score in Mexico," said Chief Executive Matthew Walls.

"The collaboration will extend our reach into this growing cardiovascular disease market and allow us to consider other tests for distribution in the region."

Shares in GENinCode fell 5.3% to 2.70 pence on Wednesday afternoon in London.

By Roya Shahidi, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Genincode